CTOs on the Move

Sienna Biopharmaceuticals

www.siennabio.com

 
Sienna Biopharmaceuticals is focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes, and physicians’ practice of medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.siennabio.com
  • 30721 Russell Ranch Road Suite 140
    Westlake Village, CA USA 91362
  • Phone: 818.629.2256

Executives

Name Title Contact Details

Funding

Sienna Biopharmaceuticals raised $34M on 04/28/2016

Similar Companies

Leap Therapeutics

Leap is developing novel drugs to change the practice of cancer medicine

Bio Analytical Research Corporation

Bio Analytical Research Corporation is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biosome

Biosome is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Delfi Diagnostics

Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.

Personalis

Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape.